Authorized use of Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5)
Pfizer-BioNTech COVID-19 Vaccine, Bivalent has not been approved or licensed by FDA, but has
been authorized for emergency use by FDA, under an EUA to prevent Coronavirus Disease 2019
(COVID-19) for use in individuals aged 6 months of age and older. The emergency use of this
product is only authorized for the duration of the declaration that circumstances exist
justifying the authorization of emergency use of the medical product under Section 564(b) (1) of
the FD&C Act unless the declaration is terminated or authorization revoked sooner.
For most recent Fact Sheets, please visit www.cvdvaccine-us.com
Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5): Authorization and Recommendation Updates
Elizabeth Thoburn, MPH
Medical Director,
Pfizer mRNA Vaccines,
Medical & Scientific Affairs, USA
Date and Time:
26 April 2023
12:00 pm – 1:00 pm EST
27 April 2023
4:00 pm – 5:00 pm EST
Select COVID-19 Vaccine Updates from February ACIP Meeting
Rajeev M Nepal, PhD
Medical Director,
Pfizer mRNA Vaccines,
Medical & Scientific Affairs, USA
Date and Time:
22 March 2023
12:00 pm – 1:00 pm EST
23 March 2023
4:00 pm – 5:00 pm EST
COVID-19 Vaccination: Considerations for Pediatric Patients
Maria D. McColgan, MD, MSEd
Medical Director,
Pfizer mRNA Vaccines,
Medical & Scientific Affairs, USA
Date and Time:
27 February 2023
12:00 PM – 1:00 PM EST
28 February 2023
5:00 PM – 6:00 PM EST
01 March 2023
3:00 PM – 4:00 PM EST
Select Bivalent COVID-19 Vaccine Information Presented at Recent FDA Advisory Committee Meeting
Rajeev M Nepal, PhD
Medical Director,
Pfizer mRNA Vaccines,
Medical & Scientific Affairs, USA
Date and Time:
13 February 2023
12:00 pm – 1:00 pm EST
14 February 2023
5:00 pm – 6:00 pm EST
15 February 2023
3:00 pm – 4:00 pm EST
Effectiveness of COVID-19 mRNA Vaccines, Bivalent (Original and Omicron BA.4/BA.5) Against Omicron Sublineages
Rajeev M Nepal, PhD
Medical Director,
Pfizer mRNA Vaccines,
Medical & Scientific Affairs, USA
Date and Time:
11 January 2023
12:00 pm – 1:00 pm EST
12 January 2023
5:00 pm – 6:00 pm EST
17 January 2023
3:00 pm – 4:00 pm EST
Neutralization of Omicron Sublineages with the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5)
Rajeev M Nepal, PhD
Medical Director,
Pfizer mRNA Vaccines,
Medical & Scientific Affairs, USA
Date and Time:
13 December 2022
12:00 pm – 1:00 pm EST
14 December 2022
5:00 pm – 6:00 pm EST
15 December 2022
3:00 pm – 4:00 pm EST
COVID-19 and COVID-19 mRNA Vaccine-Related Myocarditis
Santiago Lopez, MD
Medical Director,
Pfizer mRNA Vaccines,
Medical & Scientific Affairs, USA
Date and Time:
29 November 2022
12:00 pm –1:00 pm EST
01 December 2022
4:00 pm –5:00 pm EST
Medical Update on Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5)
Rajeev M Nepal, PhD
Medical Director,
Pfizer mRNA Vaccines,
Medical & Scientific Affairs, USA
Date and Time:
14 November 2022
12:00 pm – 1:00 pm EST
15 November 2022
5:00 pm – 6:00 pm EST
16 November 2022
3:00 pm – 4:00 pm EST
